{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:01:22Z","timestamp":1794405682439,"version":"4.9.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9-10","license":[{"start":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T00:00:00Z","timestamp":1722124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T00:00:00Z","timestamp":1722124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["21\/0006280"],"award-info":[{"award-number":["21\/0006280"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000882","name":"University of Aberdeen","doi-asserted-by":"publisher","award":["DTG"],"award-info":[{"award-number":["DTG"]}],"id":[{"id":"10.13039\/501100000882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["EASTBIO PhD Studentship"],"award-info":[{"award-number":["EASTBIO PhD Studentship"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/V015869\/1"],"award-info":[{"award-number":["BB\/V015869\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lipodystrophy is a rare disorder which can be life-threatening. Here individuals fail to develop or maintain appropriate adipose tissue stores. This typically causes severe metabolic complications, including hepatic steatosis and lipoatrophic diabetes. There is no cure for lipodystrophy, and treatment options remain very limited. Here we evaluate whether tissue-selective adeno-associated virus (AAV) vectors can provide a targeted form of gene therapy for lipodystrophy, using a preclinical lipodystrophic mouse model of\n                    <jats:italic>Bscl2<\/jats:italic>\n                    deficiency. We designed AAV vectors containing the mini\/aP2 or thyroxine-binding globulin promoter to selectively target adipose or liver respectively. The AAV-aP2 vectors also contained the liver-specific microRNA-122 target sequence, restricting hepatic transgene expression. Systemic delivery of AAV-aP2 vectors overexpressing human\n                    <jats:italic>BSCL2<\/jats:italic>\n                    restored adipose tissue development and metabolic health in lipodystrophic mice without detectable expression in the liver. High doses (1\u2009\u00d7\u200910\n                    <jats:sup>12<\/jats:sup>\n                    GCs) of liver-selective vectors led to off target expression and adipose tissue development, whilst low doses (1\u2009\u00d7\u200910\n                    <jats:sup>10<\/jats:sup>\n                    GCs) expressed selectively and robustly in the liver but did not improve metabolic health. This reveals that adipose tissue-selective, but not liver directed, AAV-mediated gene therapy is sufficient to substantially recover metabolic health in generalised lipodystrophy. This provides an exciting potential new avenue for an effective, targeted, and thereby safer therapeutic intervention.\n                  <\/jats:p>","DOI":"10.1038\/s41434-024-00471-z","type":"journal-article","created":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T10:01:24Z","timestamp":1722160884000},"page":"445-454","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Preclinical evaluation of tissue-selective gene therapies for congenital generalised lipodystrophy"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7665-0878","authenticated-orcid":false,"given":"Mansi","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6831-4426","authenticated-orcid":false,"given":"Ahlima","family":"Roumane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2380-7117","authenticated-orcid":false,"given":"Nadine","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela","family":"Delibegovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin J.","family":"Rochford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4230-4355","authenticated-orcid":false,"given":"George D.","family":"Mcilroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,28]]},"reference":[{"key":"471_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120375","volume":"294","author":"N Sayed","year":"2022","unstructured":"Sayed N, Allawadhi P, Khurana A, Singh V, Navik U, Pasumarthi SK, et al. Gene therapy: comprehensive overview and therapeutic applications. Life Sci. 2022;294:120375.","journal-title":"Life Sci"},{"key":"471_CR2","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/d41573-021-00017-7","volume":"20","author":"DA Kuzmin","year":"2021","unstructured":"Kuzmin DA, Shutova MV, Johnston NR, Smith OP, Fedorin VV, Kukushkin YS, et al. The clinical landscape for AAV gene therapies. Nat Rev Drug Discov. 2021;20:173\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"471_CR3","doi-asserted-by":"publisher","first-page":"809118","DOI":"10.3389\/fmed.2021.809118","volume":"8","author":"HKE Au","year":"2022","unstructured":"Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med. 2022;8:809118.","journal-title":"Front Med"},{"key":"471_CR4","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2337\/db19-0447","volume":"69","author":"C Gonzaga-Jauregui","year":"2020","unstructured":"Gonzaga-Jauregui C, Ge W, Staples J, Van Hout C, Yadav A, Colonie R, et al. Clinical and molecular prevalence of lipodystrophy in an unascertained large clinical care cohort. Diabetes. 2020;69:249\u201358.","journal-title":"Diabetes"},{"key":"471_CR5","first-page":"907","volume":"101","author":"K Lim","year":"2021","unstructured":"Lim K, Haider A, Adams C, Sleigh A, Savage DB. Lipodistrophy: a paradigm for understanding the consequences of \u201coverloading\u201d adipose tissue. Physiol Rev. 2021;101:907\u201393.","journal-title":"Physiol Rev"},{"key":"471_CR6","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/ng585","volume":"28","author":"J Magre","year":"2001","unstructured":"Magre J, Delepine M, Khallouf E, Gedde-Dahl T Jr, Van Maldergem L, Sobel E, et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet. 2001;28:365\u201370.","journal-title":"Nat Genet"},{"key":"471_CR7","doi-asserted-by":"publisher","first-page":"e0199052","DOI":"10.1371\/journal.pone.0199052","volume":"13","author":"JG Lima","year":"2018","unstructured":"Lima JG, Nobrega LHC, Lima NN, Dos Santos MCF, Silva PHD, Baracho MFP, et al. Causes of death in patients with Berardinelli-Seip congenital generalized lipodystrophy. PLoS ONE. 2018;13:e0199052.","journal-title":"PLoS ONE"},{"key":"471_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15214","volume":"40","author":"M Tiwari","year":"2023","unstructured":"Tiwari M, Mcilroy GD. From scarcity to solutions: therapeutic strategies to restore adipose tissue functionality in rare disorders of lipodystrophy. Diabet Med. 2023;40:e15214.","journal-title":"Diabet Med"},{"key":"471_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.omtm.2020.09.009","volume":"19","author":"R Bates","year":"2020","unstructured":"Bates R, Huang W, Cao L. Adipose tissue: an emerging target for adeno-associated viral vectors. Mol Ther Methods Clin Dev. 2020;19:236\u201349.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"471_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/gt.2014.38","volume":"21","author":"SM O\u2019Neill","year":"2014","unstructured":"O\u2019Neill SM, Hinkle C, Chen SJ, Sandhu A, Hovhannisyan R, Stephan S, et al. Targeting adipose tissue via systemic gene therapy. Gene Ther. 2014;21:653\u201361.","journal-title":"Gene Ther"},{"key":"471_CR11","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.omtm.2017.06.002","volume":"6","author":"W Huang","year":"2017","unstructured":"Huang W, Liu X, Queen NJ, Cao L. Targeting visceral fat by intraperitoneal delivery of novel AAV serotype vector restricting off-target transduction in liver. Mol Ther Methods Clin Dev. 2017;6:68\u201378.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"471_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.omtm.2022.09.014","volume":"27","author":"N Sommer","year":"2022","unstructured":"Sommer N, Roumane A, Han W, Delibegovi\u0107 M, Rochford JJ, Mcilroy GD. Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy. Mol Ther Methods Clin Dev. 2022;27:206\u201316.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"471_CR13","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.2337\/db13-0311","volume":"62","author":"V Jimenez","year":"2013","unstructured":"Jimenez V, Mu\u00f1oz S, Casana E, Mallol C, Elias I, Jambrina C, et al. In vivo adeno-associated viral vector-mediated genetic engineering of white and brown adipose tissue in adult mice. Diabetes. 2013;62:4012\u201322.","journal-title":"Diabetes"},{"key":"471_CR14","doi-asserted-by":"publisher","first-page":"dmm042655","DOI":"10.1242\/dmm.042655","volume":"13","author":"GD Mcilroy","year":"2020","unstructured":"Mcilroy GD, Mitchell SE, Han W, Delibegovi\u0107 M, Rochford JJ. Ablation of Bscl2\/seipin in hepatocytes does not cause metabolic dysfunction in congenital generalised lipodystrophy. Dis Model Mech. 2020;13:dmm042655. https:\/\/doi.org\/10.1242\/dmm.042655.","journal-title":"Dis Model Mech"},{"key":"471_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.3390\/jcm10030441","volume":"10","author":"A Roumane","year":"2021","unstructured":"Roumane A, Mcilroy GD, Balci A, Han W, Delibegovi\u0107 M, Baldassarre M, et al. Bscl2 deficiency does not directly impair the innate immune response in a murine model of generalized lipodystrophy. J Clin Med. 2021;10:441. https:\/\/doi.org\/10.3390\/jcm10030441.","journal-title":"J Clin Med"},{"key":"471_CR16","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1210\/jcem.85.7.6661","volume":"85","author":"A Katz","year":"2000","unstructured":"Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402\u201310.","journal-title":"J Clin Endocrinol Metab"},{"key":"471_CR17","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1210\/en.2014-1292","volume":"155","author":"W Chen","year":"2014","unstructured":"Chen W, Zhou H, Saha P, Li L, Chan L. Molecular mechanisms underlying fasting modulated liver insulin sensitivity and metabolism in male lipodystrophic Bscl2\/Seipin-deficient mice. Endocrinology. 2014;155:4215\u201325.","journal-title":"Endocrinology"},{"key":"471_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.bbrc.2015.02.147","volume":"460","author":"M Gao","year":"2015","unstructured":"Gao M, Wang M, Guo X, Qiu X, Liu L, Liao J, et al. Expression of seipin in adipose tissue rescues lipodystrophy, hepatic steatosis and insulin resistance in seipin null mice. Biochem Biophys Res Commun. 2015;460:143\u201350.","journal-title":"Biochem Biophys Res Commun"},{"key":"471_CR19","doi-asserted-by":"publisher","first-page":"E54","DOI":"10.1152\/ajpendo.00180.2018","volume":"316","author":"H Wang","year":"2019","unstructured":"Wang H, Xu PF, Li JY, Liu XJ, Wu XY, Xu F, et al. Adipose tissue transplantation ameliorates lipodystrophy-associated metabolic disorders in seipin-deficient mice. Am J Physiol Endocrinol Metab. 2019;316:E54\u201362.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"471_CR20","doi-asserted-by":"publisher","unstructured":"Zhou H, Lei X, Yan Y, Lydic T, Li J, Weintraub NL, et al. Targeting ATGL to rescue BSCL2 lipodystrophy and its associated cardiomyopathy. JCI Insight. 2019;5. https:\/\/doi.org\/10.1172\/jci.insight.129781.","DOI":"10.1172\/jci.insight.129781"},{"key":"471_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28:165\u201373.","journal-title":"Eur J Hum Genet"},{"key":"471_CR22","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1056\/NEJMoa012437","volume":"346","author":"EA Oral","year":"2002","unstructured":"Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, et al. Leptin-replacement therapy for lipodystrophy. N Engl J Med. 2002;346:570\u20138.","journal-title":"N Engl J Med"},{"key":"471_CR23","doi-asserted-by":"crossref","unstructured":"Roumane A, Mcilroy GD, Sommer N, Han W, Heisler LK, Rochford JJ. GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy. Front Endocrinol. 2024;15:1379228.","DOI":"10.3389\/fendo.2024.1379228"},{"key":"471_CR24","doi-asserted-by":"crossref","unstructured":"Aliyev A, Samadov E, Ibrahimli A, Hajiyev A, Allahverdiyeva G, Ahmadov E. Liver transplantation in patient with Berardinelli-Seip syndrome: a literature review and case report. Pediatr Transplant. 2024;28:e14680.","DOI":"10.1111\/petr.14680"},{"key":"471_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mce.2019.03.005","volume":"488","author":"Q Li","year":"2019","unstructured":"Li Q, Li Y, Zhang Z, Kang H, Zhang L, Zhang Y, et al. SEIPIN overexpression in the liver may alleviate hepatic steatosis by influencing the intracellular calcium level. Mol Cell Endocrinol. 2019;488:70\u20138.","journal-title":"Mol Cell Endocrinol"},{"key":"471_CR26","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/gt.2010.157","volume":"18","author":"C Qiao","year":"2011","unstructured":"Qiao C, Yuan Z, Li J, He B, Zheng H, Mayer C, et al. Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther. 2011;18:403\u201310.","journal-title":"Gene Ther"},{"key":"471_CR27","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1194\/jlr.M060244","volume":"56","author":"H Zhou","year":"2015","unstructured":"Zhou H, Lei X, Benson T, Mintz J, Xu X, Harris RB, et al. Berardinelli-Seip congenital lipodystrophy 2 regulates adipocyte lipolysis, browning, and energy balance in adult animals. J Lipid Res. 2015;56:1912\u201325.","journal-title":"J Lipid Res"},{"key":"471_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.molmet.2018.01.019","volume":"10","author":"GD Mcilroy","year":"2018","unstructured":"Mcilroy GD, Suchacki K, Roelofs AJ, Yang W, Fu Y, Bai B, et al. Adipose specific disruption of seipin causes early-onset generalised lipodystrophy and altered fuel utilisation without severe metabolic disease. Mol Metab. 2018;10:55\u201365.","journal-title":"Mol Metab"},{"key":"471_CR29","doi-asserted-by":"publisher","first-page":"17863","DOI":"10.1038\/s41598-018-36078-9","volume":"8","author":"GD Mcilroy","year":"2018","unstructured":"Mcilroy GD, Mitchell SE, Han W, Delibegovic M, Rochford JJ. Female adipose tissue-specific Bscl2 knockout mice develop only moderate metabolic dysfunction when housed at thermoneutrality and fed a high-fat diet. Sci Rep. 2018;8:17863\u20139.","journal-title":"Sci Rep"},{"key":"471_CR30","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1038\/s41467-019-11321-7","volume":"10","author":"JF Lang","year":"2019","unstructured":"Lang JF, Toulmin SA, Brida KL, Eisenlohr LC, Davidson BL. Standard screening methods underreport AAV-mediated transduction and gene editing. Nat Commun. 2019;10:3415\u20137.","journal-title":"Nat Commun"},{"key":"471_CR31","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/978-1-4939-9139-6_23","volume":"1950","author":"W Huang","year":"2019","unstructured":"Huang W, Queen NJ, Cao L. rAAV-mediated gene delivery to adipose tissue. Methods Mol Biol. 2019;1950:389\u2013405.","journal-title":"Methods Mol Biol"},{"key":"471_CR32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21:255\u201372.","journal-title":"Nat Rev Genet"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00471-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00471-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00471-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T05:13:08Z","timestamp":1726204388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-024-00471-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,28]]},"references-count":32,"journal-issue":{"issue":"9-10","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1038\/s41434-024-00471-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.06.27.600757","asserted-by":"object"}]},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,28]]},"assertion":[{"value":"3 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GDM and JJR are co-inventors on a patent application for the use of gene therapies designed for the treatment of conditions of lipodystrophy.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Procedures on wild type (WT) and seipin knockout (SKO) mice were approved by the University of Aberdeen Ethics Review Board and performed under the Animals (Scientific Procedures) Act 1986 under project license (PPL: P1ECEB2B6) approved by the UK Home Office.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}